Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of injectable BL-M09D1 in advanced or metastatic gynecologic malignancies and other solid tumors
CTR20263134Phase 2Active
- Sponsor
- Biokin Pharmaceutical
- Start
- Aug 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of BL-M09D1 in endometrial cancer (EC), Cervical Cancer (CC), ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Biokin Pharmaceutical. Started Aug 2026; status: active.
02
Drugs
BL-M09D1
03
Conditions
endometrial cancer (EC)Cervical Cancer (CC)ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on CTR20263134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263134.